Voyager Technologies (NYSE: VOYG) has signed a contract with the Center for the Advancement of Science in Space to manage a cancer research experiment aboard the International Space Station (ISS) on behalf of Symphony Biosciences.

The experiment involves SymphNode, a biopolymer implant developed by Symphony Biosciences that is designed to restore immune response under immunosuppressive conditions by recruiting and activating a patient's T cells to target cancer cells. The ISS study aims to replicate in vitro research conducted on Earth using human T cells and tumor cells to assess the efficacy of immune cells trained within the device.

Under the contract, Voyager will adapt Symphony Biosciences' hardware to station equipment, manage NASA safety reviews, and oversee integration and stowage for launch. Voyager mission managers will also monitor on-orbit operations, including incubation and fluorescence readings, and assist astronauts in conducting the experiment. Upon conclusion, Voyager will return samples and data and provide post-flight reporting.

"Microgravity provides a cancer research environment where tumor cells form complex, three-dimensional structures that are obscured in Earth cultures," said Scott Rodriguez, vice president of Government Programs at Voyager.

According to the press release, Voyager has accumulated more than 1,400 missions over two decades of flight operations.